

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF TASLY PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2025

On 19 March 2026, Tasly Pharmaceutical released its annual report for the year ended 31 December 2025.

Tasly Pharmaceutical Group Co., Ltd. (天士力醫藥集團股份有限公司) (“**Tasly Pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of Tasly Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Tasly Pharmaceutical is owned as to approximately 28.00% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), through its non-wholly-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”), and is accounted for as a subsidiary of the Company.

On 19 March 2026, Tasly Pharmaceutical released its annual report for the year ended 31 December 2025 (the “**Tasly Pharmaceutical Audited Annual Financials**”). Set out below are the key financial information of the Tasly Pharmaceutical Audited Annual Financials:

	For the year ended 31 December		Increase/ decrease (%)
	2025 (RMB) (Audited)	2024 (RMB) (Audited)	
Revenue	8,236,477,437.80	8,498,141,862.15	-3.08%
Net profit attributable to the shareholders of the listed company	1,104,961,925.73	955,586,168.91	15.63%
Net profit attributable to the shareholders of the listed company (after extraordinary gains or losses)	791,345,927.46	1,035,706,322.69	-23.59%
Net cash flow from operating activities	1,424,751,577.01	2,014,559,042.35	-29.28%
Basic earnings per share (RMB/share)	0.74	0.64	15.63%

	For the year ended 31 December		Increase (%)
	2025 (RMB) (Audited)	2024 (RMB) (Audited)	
Diluted earnings per share (RMB/share)	0.74	0.64	15.63%
Weighted average return on net asset (%)	9.09%	7.68%	1.41 percentage points
	As of 31 December 2025 (RMB) (Audited)	As of 31 December 2024 (RMB) (Audited)	Increase (%)
Total assets	15,339,719,707.15	14,976,295,362.69	2.43%
Net assets attributable to shareholders of the listed company	12,404,228,392.95	11,903,329,002.35	4.21%

As determined by the board of directors of Tasly Pharmaceutical, Tasly Pharmaceutical proposed to distribute a cash dividend of RMB1 (inclusive of tax) for every 10 shares to all Tasly Pharmaceutical's shareholders based on the total share capital of Tasly Pharmaceutical on the date of equity distribution registration. Such proposal shall be submitted for shareholders' approval at Tasly Pharmaceutical's 2025 annual general meeting.

The Tasly Pharmaceutical Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to Tasly Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Tasly Pharmaceutical Audited Annual Financials, please refer to the annual report for the year ended 31 December 2025 published by Tasly Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 19 March 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.